News

January 20, 2022
Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
January 11, 2022
Oncolytics Biotech® Releases a Letter to Shareholders – 2021 Review and 2022 Outlook
December 21, 2021
Oncolytics Biotech® Promotes Thomas C. Heineman, M.D., Ph.D., to Chief Medical Officer
December 15, 2021
Oncolytics Biotech® Announces the Presentation of Preclinical Data Demonstrating the Synergistic Anti-Leukemic Effects of Pelareorep Combined with Azacitidine at the 2021 American Society of Hematology Annual Meeting
December 10, 2021
Oncolytics Biotech® Presents Positive Interim Safety Update from Phase 2 Triple-Negative Breast Cancer Trial at the 2021 San Antonio Breast Cancer Symposium
November 19, 2021
Oncolytics Biotech® to Present Phase 2 Triple-Negative Breast Cancer Trial Update at the 2021 San Antonio Breast Cancer Symposium
November 5, 2021
Oncolytics Biotech® Reports 2021 Third Quarter Development Highlights and Financial Results
November 3, 2021
Oncolytics Biotech® Doses First Patient in Phase 1/2 GOBLET Study Evaluating Pelareorep-anti-PD-L1 Combination Therapies in Gastrointestinal Cancers
October 19, 2021
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights
October 14, 2021
Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

Investor Relations Contact

Jon Patton
Director of Investor Relations & Communication
Email: jpatton@oncolytics.ca

Email Alerts Sign-Up